Justin W. Yorke is Director at Processa Pharmaceuticals, Inc. (PCSA). They have made 5 open-market trades across 1 company since 2021, most recently 2026-06-26.
CIK 0001361896
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
2 open-market purchases totalling $31K since 2024, against 3 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| PCSA | 353 | $591 |
Shares reported on the most recent Form 4, priced at the 2026-06-30 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| PCSA | BUY | 2025-01-27 | 2025-01-31 | $0.80 | $10K | -6.2% | -24.4% | -61.5% |
| PCSA | BUY | 2024-01-30 | 2024-01-31 | $2.69 | $22K | +2.5% | +1.7% | -9.9% |
| PCSA | SELL | 2022-01-27 | 2022-01-31 | $3.30 | $6K | +8.0% | +10.8% | -26.0% |
| PCSA | SELL | 2021-12-03 | 2021-12-07 | $4.78 | $46K | +15.1% | +10.3% | -18.6% |
| PCSA | SELL | 2021-04-13 | 2021-04-15 | $9.67 | $220K | -6.5% | -32.9% | -25.1% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.